menu search

Biogen's alzheimer's drug rollout could be slow

Biogen has said it doesn't expect to clear a profit on alzheimer's treatment Leqembi, which was approve...

July 7, 2023, 1:17 pm

Eisai-biogen's alzheimer's treatment drug receives fda approval

Shares of Biogen and Eisai are lower amid news of label updates to the FDA officially approved the alzheimer...

July 7, 2023, 11:15 am

Demand for biogen's new alzheimer's drug will surprise to the upside, says piper sandler analyst

Christopher Raymond, Piper Sandler, joins 'Squawk on the Street' to discuss the market's reaction to Biogen's FDA approval, what demand will look like...

July 7, 2023, 11:06 am

Will watershed moment for alzheimer's propel biogen stock higher?

Esai and Biogen's alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Ful...

July 7, 2023, 10:20 am

5 things to know before markets open

The government's latest jobs report is expected to show continued strength in the labor market and the FDA gives approval to a new ...

July 7, 2023, 7:50 am

Biogen's stock slides premarket as analysts take mixed view of alzheimer's disease drug approval

Biogen Inc.'s stock BIIB, -0.31% rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday gra...

July 7, 2023, 7:29 am

alzheimer's drug, the first to slow disease progression, gets fda green light

Eisai, a Japanese firm, and American drugs giant Biogen Inc (NASDAQ:BIIB) have received full Food & Drug Administration approval for Leqembi, a ground...

July 7, 2023, 2:58 am

Many health systems are already ready for 'leqembi' roll out, says eisai ceo ivan cheung

Ivan Cheung, Eisai U.S. CEO, joins 'Fast Money' to discuss the FDA approving Biogen's 'Leqembi' alzheimer...

July 6, 2023, 7:03 pm

Fda approves leqembi, extending alzheimer's treatment to more patients

Medicare enrollees can get the anti-amyloid treatment as a result of the agency's full approval....

July 6, 2023, 6:57 pm

First drug to slow progression of alzheimer's disease approved in us

The US Food and Drug Administration (FDA) has fully approved a drug that slows the progression of alzheimer...

July 6, 2023, 6:44 pm

Fda grants full approval for alzheimer's drug, despite concerns

Leqembi costs $26,000 per year before insurance....

July 6, 2023, 5:30 pm

Fda approves biogen and eisai alzheimer's treatment leqembi

The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen BIIB and Eisai Co. Ltd. ESALF ...

July 6, 2023, 4:55 pm

Fda approves alzheimer's drug leqembi, paving way for broader medicare coverage

Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding....

July 6, 2023, 4:44 pm

Cassava sciences (sava) stock drops despite positive trial results

Cassava Sciences (NASDAQ: SAVA ) stock is well in the red today despite announcing Phase 3 results for its alz...

July 5, 2023, 3:38 pm

Cassava sciences: why market skepticism persists despite positive findings on simufilam

Cassava Sciences' alzheimer's drug, simufilam, reduced cognitive decline by 38% in a small study, but t...

July 5, 2023, 3:05 pm

Why shares of cassava sciences are dropping wednesday

Simufilam slowed cognitive decline by 38% compared to a placebo after six months for patients with mild to moderate ...

July 5, 2023, 11:44 am

Why shares of ac immune jumped this week

AC Immune is a clinical-stage biotech with 16 programs in its pipeline. It is attempting to develop an alzheim...

June 30, 2023, 3:13 pm

Lonza: our thoughts pre capital market day, buy confirmed

Despite a challenging economic environment, Lonza announced an increase in CAPEX, positioning itself to capture long-term growth opportunities in the ...

June 30, 2023, 3:41 am

Hagens berman, national trial attorneys, encourages bioxcel therapeutics (btai) investors with substantial losses to contact firm, firm investigating possible securities law violations

SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) — Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial los...

June 29, 2023, 10:12 pm

Bioxcel therapeutics announces positive topline results from tranquility ii phase 3 trial of bxcl501 for acute treatment of alzheimer’s disease-related agitation

Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC score from baseli...

June 29, 2023, 10:00 am


Search within

Pages Search Results: